Irmed Klimkiewicz Rudziewicz-Kowalska sp. j.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Irmed Klimkiewicz Rudziewicz-Kowalska sp. j. includes a strong focus on cardiovascular diseases, with studies in heart failure, hypertension, atherosclerotic cardiovascular disease, and elevated lipoprotein(a). These trials are designed to assess new treatments, improve risk reduction, and better manage serious heart and blood vessel conditions.
- Testing therapies for heart failure with preserved ejection fraction and heart failure with reduced ejection fraction
- Evaluating treatments for hypertension in people with obesity or higher cardiovascular risk
- Studying approaches to lower major cardiovascular event risk in established cardiovascular disease
The site is also involved in research aimed at improving prevention strategies for people at increased risk of cardiovascular events.
Digestive System Diseases
Trials in digestive system diseases at this research site focus on ulcerative colitis and Crohn’s disease. The main goal is to evaluate new and existing therapies that may help control inflammation, support remission, and improve overall disease management.
- Assessing treatment effectiveness in moderately to severely active ulcerative colitis
- Studying combined approaches for Crohn’s disease with coexisting obesity or overweight
- Comparing therapies intended to improve clinical and endoscopic remission
This area reflects a broad effort to advance care for chronic inflammatory bowel conditions.
Musculoskeletal Diseases
The site is also conducting research in musculoskeletal diseases, particularly moderate to severe rotator cuff tendinopathy. These studies aim to improve symptom relief and functional outcomes for people living with shoulder pain and mobility limitations.
- Evaluating a therapy for shoulder symptoms linked to rotator cuff tendinopathy
- Measuring whether treatment can improve physical function and daily comfort
The focus is on finding better ways to ease pain and support recovery in common orthopedic conditions.
Nervous System Diseases
In nervous system diseases, the clinical trials include work in multiple sclerosis. Research here is centered on reducing relapses and improving long-term disease control for people living with this chronic neurological condition.
- Studying treatments for relapsing multiple sclerosis
- Evaluating options that may better control symptom flare-ups
- Looking at therapies intended to support longer-term disease stability
These studies aim to expand treatment choices for patients affected by progressive neurological disability.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic diseases covers obesity, overweight, and type 1 diabetes. The trials are designed to assess better ways to support weight reduction, improve metabolic control, and simplify diabetes management.
- Testing therapies for weight management in people with obesity or overweight
- Evaluating treatment strategies for type 1 diabetes and glycaemic control
- Exploring combined approaches that address both metabolic health and related cardiovascular risk
This work highlights a strong interest in conditions where metabolism and cardiovascular health overlap.
Respiratory Tract Diseases
The site’s portfolio also includes research linked to respiratory tract diseases, reflecting broader interest in chronic inflammatory and systemic conditions that can affect breathing and overall health. The trials in this area are aimed at improving treatment effectiveness and patient outcomes.
- Investigating therapies for respiratory-related inflammatory conditions
- Supporting efforts to improve symptom control and quality of life
This adds to the site’s diverse clinical research profile across multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Eli Lilly & Co.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Irmed Klimkiewicz Rudziewicz-Kowalska sp. j.
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-Blind Study Comparing Remibrutinib and Teriflunomide in Relapsing Multiple Sclerosis Patients, with Open-Label Remibrutinib Extension | Novartis Pharma AG | Phase III | Not Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.